NVO

CNBC's Jim Cramer, host of Mad Money, posted on X on Monday, “Hard to believe the drug stocks are so out of sync with food stocks.

Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising competition remain key risks.

NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.

Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, ‌and that new treatment options like pills will keep it from becoming a winner-take-all battle with rival Eli Lilly.

Novo Nordisk CEO argues weight loss drugs could slash health care costs and boost productivity as GLP-1 adoption remains in its early innings.

NVO faces near-term pressure from flat Wegovy sales, pricing challenges and pipeline setbacks, but its broad cardiometabolic pipeline offers long-term potential.

Novo Nordisk President and CEO Mike Doustdar discusses the company's collaboration with artificial intelligence to accelerate drug discovery and development. #foxnews #fox #novonordisk #ai #drugdiscovery #pharma #aws #artificialintelligence #healthcare #biotech #technology #healthtech #medicine #innovation #tech

Novo Nordisk remains a Buy, underpinned by strong long-term fundamentals and a promising lead in obesity care, especially with the Wegovy pill. Despite near-term challenges—declining gross margins, high CapEx, and a failed ziltivekimab trial—Novo Nordisk's operating margins and capital allocation remain robust. Management raised 2026 guidance, now expecting adjusted sales and operating profit to decline up to 6%, a significant improvement from prior outlooks.

Novo Nordisk (NVO -1.17%) is more than just a weight loss company.

Novo Nordisk A/S receives a Sell rating due to falling profits, weak revenue growth, and operational missteps despite its blockbuster semaglutide franchise. NVO's 2026 guidance signals flat to negative sales and operating profit growth, contrasting sharply with Eli Lilly's robust growth trajectory and diversified pipeline. Patent expiries, manufacturing setbacks, and pipeline disappointments undermine NVO's first-mover advantage in obesity and diabetes, while competition intensifies.